Apogee Enterprises Inc. (APOG)
Here's Why Apogee Enterprises (APOG) Could be Great Choice for a Bottom Fisher
Apogee Enterprises (APOG) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Do Options Traders Know Something About Apogee Stock We Don't?
Investors need to pay close attention to APOG stock based on the movements in the options market lately.
Wall Street Analysts See a 25.23% Upside in Apogee Enterprises (APOG): Can the Stock Really Move This High?
The consensus price target hints at a 25.2% upside potential for Apogee Enterprises (APOG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Apogee Q1 Earnings Beat Estimates on Pricing, Productivity Gains
APOG beat Q1 earnings and revenue estimates as pricing, productivity gains and Project Fortify savings help offset lower volume and higher costs.
APOG Q1 Earnings Call Keeps Focus on Kalwall, Guidance
Apogee keeps fiscal 2027 guidance intact as pricing, Fortify savings and the pending Kalwall deal frame its response to soft demand.
Apogee Enterprises: Hedge Against AI Portfolio Risk
Apogee Enterprises delivered a double-beat quarter and raised its FY2027 outlook, sparking a 15% stock surge. I initiate APOG with a buy rating, citing its turnaround potential and appeal as an anti-AI, diversification candidate. The Kalwall acquisition adds an $85 million revenue run rate, complementing cost-cutting and buyback strategies.
Apogee Enterprises, Inc. (APOG) Q1 2027 Earnings Call Transcript
Apogee Enterprises, Inc. (APOG) Q1 2027 Earnings Call Transcript
Apogee Enterprises (APOG) Beats Q1 Earnings and Revenue Estimates
Apogee Enterprises (APOG) came out with quarterly earnings of $0.57 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.56 per share a year ago.
New Strong Sell Stocks for June 2nd
APOG, BIDU and EGO have been added to the Zacks Rank #5 (Strong Sell) List on June 2nd, 2026.
Apogee Expands Architectural Glass Segment With Kalwall Buyout
APOG's $115M Kalwall buyout expands its architectural glass portfolio with high-performance daylighting solutions.
Apogee Therapeutics lines up $1.3B strategic financing for zumilokibart program
Apogee Enterprises (NASDAQ:APOG) has entered a strategic financing collaboration with Blackstone Life Sciences for up to $1.3 billion in non-dilutive capital, combining up to $800 million in synthetic royalty financing with as much as $500 million in senior corporate debt, giving the immunology developer runway to advance Phase 3 development and potential commercialization of its lead candidate zumilokibart. The financing structure pairs royalty-based capital tied to future product revenue with senior debt capacity.
Apogee Enterprises, Inc. (APOG) Q4 2026 Earnings Call Transcript
Apogee Enterprises, Inc. (APOG) Q4 2026 Earnings Call Transcript
